INNATE PHARMA SA-SPONS ADR (IPHA) Stock Price, Quote, News and Overview
NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR - Currency: USD
IPHA Quote, Performance and Key Statistics
NASDAQ:IPHA (6/2/2025, 9:37:08 AM)
2.18
-0.01 (-0.46%)
The current stock price of IPHA is 2.18 USD. In the past month the price decreased by -1.13%. In the past year, price decreased by -20.07%.
IPHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 327.86B | ||
| AMGN | AMGEN INC | 13.83 | 154.43B | ||
| GILD | GILEAD SCIENCES INC | 14.18 | 136.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.03 | 52.78B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.54B | ||
| ARGX | ARGENX SE - ADR | 100.57 | 35.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.29 | 26.56B | ||
| NTRA | NATERA INC | N/A | 21.45B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.79 | 14.46B |
Related stock screener links
About IPHA
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
INNATE PHARMA SA-SPONS ADR
117 avenue de Luminy, Bp 30191
Marseille PACA 13009 FR
CEO: Mondher Mahjoubi
Employees: 181
Phone: 33430303030
INNATE PHARMA SA-SPONS ADR / IPHA FAQ
What is the stock price of INNATE PHARMA SA-SPONS ADR today?
The current stock price of IPHA is 2.18 USD. The price decreased by -0.46% in the last trading session.
What is the ticker symbol for INNATE PHARMA SA-SPONS ADR stock?
The exchange symbol of INNATE PHARMA SA-SPONS ADR is IPHA and it is listed on the Nasdaq exchange.
On which exchange is IPHA stock listed?
IPHA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INNATE PHARMA SA-SPONS ADR stock?
11 analysts have analysed IPHA and the average price target is 6.18 USD. This implies a price increase of 183.68% is expected in the next year compared to the current price of 2.18. Check the INNATE PHARMA SA-SPONS ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INNATE PHARMA SA-SPONS ADR worth?
INNATE PHARMA SA-SPONS ADR (IPHA) has a market capitalization of 200.90M USD. This makes IPHA a Micro Cap stock.
How many employees does INNATE PHARMA SA-SPONS ADR have?
INNATE PHARMA SA-SPONS ADR (IPHA) currently has 181 employees.
What are the support and resistance levels for INNATE PHARMA SA-SPONS ADR (IPHA) stock?
INNATE PHARMA SA-SPONS ADR (IPHA) has a support level at 2.05 and a resistance level at 2.36. Check the full technical report for a detailed analysis of IPHA support and resistance levels.
Is INNATE PHARMA SA-SPONS ADR (IPHA) expected to grow?
The Revenue of INNATE PHARMA SA-SPONS ADR (IPHA) is expected to grow by 86.96% in the next year. Check the estimates tab for more information on the IPHA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INNATE PHARMA SA-SPONS ADR (IPHA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IPHA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IPHA, evaluating the profitability, health, valuation and growth aspects
- INNATE PHARMA SA-SPONS ADR (IPHA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INNATE PHARMA SA-SPONS ADR (IPHA) Sales and EPS estimates to see what analysts future expectations are.
- INNATE PHARMA SA-SPONS ADR (IPHA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INNATE PHARMA SA-SPONS ADR (IPHA) Insider and Institutional Ownership to learn about the owners and their transactions.
- INNATE PHARMA SA-SPONS ADR (IPHA) Stock Chart to make your own analysis
- INNATE PHARMA SA-SPONS ADR (IPHA) Latest news and press-releases to stay up to date.
Does INNATE PHARMA SA-SPONS ADR (IPHA) stock pay dividends?
IPHA does not pay a dividend.
When does INNATE PHARMA SA-SPONS ADR (IPHA) report earnings?
INNATE PHARMA SA-SPONS ADR (IPHA) will report earnings on 2025-09-17.
What is the Price/Earnings (PE) ratio of INNATE PHARMA SA-SPONS ADR (IPHA)?
INNATE PHARMA SA-SPONS ADR (IPHA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the Short Interest ratio of INNATE PHARMA SA-SPONS ADR (IPHA) stock?
The outstanding short interest for INNATE PHARMA SA-SPONS ADR (IPHA) is 0.62% of its float. Check the ownership tab for more information on the IPHA short interest.
IPHA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IPHA. When comparing the yearly performance of all stocks, IPHA is a bad performer in the overall market: 70.71% of all stocks are doing better.
IPHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPHA. IPHA has a bad profitability rating. Also its financial health evaluation is rather negative.
IPHA Financial Highlights
Over the last trailing twelve months IPHA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -549.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.54% | ||
| ROE | -560.01% | ||
| Debt/Equity | 8.02 |
IPHA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to IPHA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 121.73% and a revenue growth 86.96% for IPHA